Entero Targets 5% EBITDA Margin, 50% OCF Conversion in FY27

Entero Healthcare Solutions Limited — Q4 FY26 Earnings Conference Call (May 26, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly frames results as “delivered on each of those parameters” and emphasizes “optimism and confidence for the next financial year.”
• Guidance is given with clear targets and conversion metrics (e.g., EBITDA margin, OCF conversion), and they state they are “not including any new acquisitions” in FY27 guidance.

2. Key Themes from Management Commentary

• Strong FY26 delivery vs stated targets
• Revenue growth: 31.5% like-for-like (INR 6,591 cr top line)
• EBITDA margin: 4.0% (INR 266 cr EBITDA)
• Operating cash flow: INR 96.2 cr with improving working capital days
• ROCE/ROE improvement: ROCE 14.6% (from 10.7%), ROE 12.5% (from 7.7%)
• MedTech expansion as a strategic pivot
• 7 acquisitions in FY26, including 3 MedTech deals (Anand Chemiceutics, Ace Cardiopathy, Bio de Technology)
• MedTech now contributes >INR 1,000 cr annualized revenue
• Management positions MedTech as synergistic and margin-accretive (commercial role + demand generation)
• Working capital optimization is a core lever
• Net working capital days improved to 59 days in Q4 (from 64 in prior quarter)
• FY27 emphasis: cash conversion (at least 50% EBITDA → OCF)
• Guidance strategy: growth with profitability and cash discipline
• FY27 consolidated revenue growth target 23% YoY excluding new acquisitions
• FY27 EBITDA margin target 5%
• They explicitly avoid relying on new acquisitions for FY27 upside.

3. Q&A Analysis

Theme A: Minority interest / accounting effects on PAT & margins

• Core questions
• Why did minority interest jump in Q4 and does it distort profitability/margins?
• What should analysts assume for minority interest going forward?
• Management response
• Explained as “abnormal contribution from one of our subsidiaries” due to partial stake and timing.
• Provided quantitative framing:
  • Q4 minority interest was ~38% of PAT
  • Next year: minority interest contribution to PAT before minority interest: ~25% to 27%
  • Minority interest share expected to reduce by 10% to 12%.
• Assessment
• Partially strong: management gave numbers and a specific cause (timing/preponed sales).
• Potentially evasive: they did not fully reconcile whether the minority-interest timing also affects EBITDA run-rate beyond PAT leakage (analyst pressed on whether EBITDA margin guidance is “inflated” by the same abnormality).

Theme B: FY27 growth math (organic vs calendarization vs GLP-1 impact)

• Core questions
• Does the 23% FY27 growth include calendarization of FY26 acquisitions?
• How much of growth is tied to GLP-1 demand and how will Entero avoid losing share as generics enter?
• Management response
• Confirmed: 23% includes calendarization; calendarization impact is ~11%.
• GLP-1:
  • GLP-1 is a small portion of overall IPM, but Entero expects disproportionate share due to cold chain + specific manufacturers.
  • GLP-1 is “built into our growth guidance.”
• Assessment
• Unusually strong: they quantified calendarization and stated GLP-1 share mechanics (cold chain + limited GLP-1 players).
• Hedged: they avoided giving a precise GLP-1 incremental revenue number, instead using portfolio-share logic.

Theme C: Working capital sustainability & OCF conversion

• Core questions
• Payables-driven working capital movement: is it sustainable?
• Will FY27 see working capital drawdown given acquisitions are slowing?
• How should working capital % of sales trend?
• Management response
• Payables increase attributed to higher MedTech contribution (different credit terms vs pharma).
• FY27 cash discipline: “whatever EBITDA we generate, at least 50% will get converted to cash flow.”
• They argued working capital is already “built in”:
  • Q4 revenue ~INR 1,900 cr; annualized ~INR 8,000 cr
  • Incremental working capital should be limited unless growth exceeds guidance.
• Assessment
• Strong: clear explanation of payables vs inventory/receivables and a conversion target.
• Potentially optimistic: assumes working capital “already in place” without fully addressing whether MedTech payables normalize later.

Theme D: Margin drivers (gross margin expansion, MedTech commercial role)

• Core questions
• What drives gross margin expansion (procurement vs channel mix)?
• What is the margin structure in MedTech vs pharma?
• Management response
• Gross margin expansion driven by:
  • scale-led purchasing economies
  • increased commercial role (demand generation / agency-like model)
• They quantified:
  • >10% to 15% of sales from “full commercial role” model
  • incremental margins in such models could be “at least double of normal distribution margin.”
• MedTech contribution to revenue expected >15%, aspiration up to 20% in 2–3 years.
• Assessment
• Strong: management linked margin to business model (commercial role) rather than only “scale.”
• Limited transparency: they did not provide MedTech-specific EBITDA margin numbers (declined to disclose product-wise margins).

Theme E: Interest cost, depreciation, and whether these are sustainable

• Core questions
• Will finance cost come down in FY27?
• Depreciation up sharply—will it persist?
• Management response
• Finance cost: expected stable near term, then sequentially down as IPO funds deployed and debt levels stabilize.
• Depreciation: higher due to MedTech model where machines are placed at customer labs under rental/contract arrangements (IVD segment).
• Assessment
• Clear: they explained depreciation mechanics by segment (IVD rental model).

Theme F: Acquisition strategy: stop/slowdown and quality

• Core questions
• If no new acquisitions in FY27, what drives growth and how will MedTech be built organically?
• Are they still open to acquisitions?
• Management response
• FY27 guidance excludes new acquisitions; focus is organic growth and chewing through acquired platform.
• Still open to acquisitions if value accretive; could revise guidance upwards.
• They explicitly said they don’t need more MedTech companies to reach INR 1,000 cr base; pipeline exists but they prefer organic build.
• Assessment
• Credible narrative shift: from “acquisitions as growth engine” to “organic build on acquired platform.”

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 consolidated revenue growth: 23% YoY (excluding any new acquisitions)
• FY27 EBITDA margin: 5%
• FY27 EBITDA → Operating cash flow conversion: ≥ 50%
• FY27 tax rate: 22%–23%
• Minority interest (qualitative-to-quantitative framing):
• Minority interest expected to normalize; management suggested ~25% to 27% of PAT before minority interest contribution.

Implicit signals (qualitative)

• No new acquisitions planned for FY27 (but “not walking away” from opportunities).
• Margin expansion expected from:
• gross margin expansion
• operating leverage
• giving up low-margin businesses
• Working capital discipline is expected to be supported by:
• already-built working capital base from FY26 acquisitions
• MedTech payables dynamics (credit terms) rather than inventory/receivable deterioration.

5. Standout Statements (direct / high-signal)

• “We have delivered on each of those parameters.” (FY26 targets: revenue growth, EBITDA margin, OCF)
• FY27 guidance framing: “Our focus would be on profitable revenue growth and operational efficiencies to drive margins.”
• Cash conversion commitment: “We aim to deliver EBITDA to operating cash flow conversion ratio to be at least 50%.”
• MedTech growth aspiration: “It can go up to 20%” (MedTech revenue proportion in 2–3 years)
• Acquisition stance: “For next 6 to 8 months, we are only going to focus on delivering organic growth… But… we are not walking away from looking at any new acquisition opportunity.”
• Minority interest normalization: “Over next year, it’s going to normalize.”
• Moat narrative: “It’s a 2-way moat… more companies come to you because we have so much of customers and more customers come to you because we have so many companies.”

6. Red Flags / Positive Signals

Red flags
– Minority interest explanation relies on timing (“preponed sales”), but analysts pressed whether this also distorts margin run-rate; management did not fully quantify EBITDA normalization impact.
– Working capital sustainability: payables-driven improvement could reverse if MedTech credit terms normalize; management assumes stability via conversion target.
– GLP-1 impact: management claims GLP-1 is “built into guidance” but provides limited quantification of incremental revenue/margin.

Positive signals
– Clear, quantified FY27 targets including cash conversion (rarely given with specificity).
– Management explicitly states FY27 excludes new acquisitions, reducing “acquisition-driven” optimism risk.
– MedTech strategy is operationally grounded (commercial role, demand generation, rental model explanation for depreciation).

7. Historical Comparison & Consistency Analysis (vs prior 3–4 calls)

a. Change in Tone Over Time

• Q1 FY26 (Aug 2025): optimistic, emphasizing disciplined M&A and working capital reduction; guided FY26 30% revenue growth and 4%+ EBITDA.
• Q2 FY26 (Nov 2025): still confident; reiterated FY26 trajectory and cash flow target INR100 cr+ OCF; emphasized MedTech acquisitions and pro-forma margin uplift.
• Q3 FY26 (Feb 2026): strong quarter; reiterated being on track for FY26 guidance; continued working capital improvements.
• Q4 FY26 (May 2026): tone remains optimistic but becomes more “execution-confirming” (“delivered on each parameter”) and more forward-looking with explicit FY27 cash conversion.

Shift classification: More Optimistic / No Change (leaning more optimistic due to stronger FY27 specificity and “delivered on guidance” framing).

b. Tracking Past Commitments vs Outcomes

• FY26 EBITDA margin target 4%+
• Past statement: Q1 FY26: “surpass 4% full-year EBITDA margins” (and later calls reiterated).
• Outcome in Q4 FY26: Delivered 4.0%.
• ✅ Delivered
• FY26 OCF target INR100 cr+ (or positive OCF)
• Past statement: Q2 FY26: “operating cash flow… range of INR100 crores plus.”
• Outcome in Q4 FY26: Operating cash flow INR96.2 cr (slightly below INR100 cr but close; management also highlighted working capital improvement and conversion).
• ⏳ Delayed / Slight miss (depends on whether “range” was interpreted as “around 100”; management did not claim “100+” in FY26 summary)
• Working capital target ~60 days
• Past statement: Q1/Q2: target ~60 days by year-end.
• Outcome in Q4 FY26: 59 days in Q4.
• ✅ Delivered
• Acquisition slowdown / integration focus
• Past statement (Q3 FY26): “next 2–3 quarters… focus on integrating… improve margins, improve cash flows.”
• Outcome in Q4 FY26: management now explicitly says FY27 guidance excludes new acquisitions and focuses on organic growth.
• ✅ Delivered (narrative alignment)

c. Narrative Shifts

• From “M&A-led growth” to “platform-led organic growth”
• Earlier calls heavily emphasized acquisition pipeline and pro-forma MedTech margin uplift.
• In Q4 FY26, management explicitly guides FY27 without new acquisitions, shifting emphasis to organic execution and cash conversion.
• MedTech emphasis increases
• MedTech moved from “new segment expansion” (Q1/Q2) to a core contributor with >15% revenue aspiration and commercial role margin mechanics (Q4).

d. Consistency & Credibility Signals

• High credibility on operational levers: working capital days and margin expansion are repeatedly tracked and ultimately achieved (60 days, 4% EBITDA).
• Credibility mixed on cash flow magnitude: OCF guidance was repeatedly framed as INR100 cr+, but FY26 reported INR96.2 cr—not a large miss, but still a deviation.
• Minority interest / accounting effects: management provides explanations, but the Q&A shows analysts remain unconvinced about run-rate implications.

Overall credibility (communication consistency): Medium-High

e. Evolution of Key Themes

• Demand / category tailwinds (GLP-1): becomes more explicit by Q4 FY26 (“built into guidance”).
• Margins: consistently attributed to mix + procurement + operating leverage; Q4 adds “giving up low-margin businesses.”
• Cash conversion: becomes more quantified in Q4 (≥50% EBITDA→OCF), whereas earlier calls focused more on OCF targets.
• Acquisitions: pace appears to be intentionally reduced; Q4 confirms “no new acquisitions” in FY27 guidance.

f. Additional Insights (cross-period intelligence)

• Cash flow guidance appears to have been tightened/managed: management now emphasizes conversion ratio rather than absolute OCF “INR100+” language, suggesting a more conservative stance after FY26 OCF came in slightly below the earlier “100+” framing.
• Minority interest is increasingly relevant: as more deals are partial-stake with call options, minority interest becomes a recurring analytical focus; management’s explanations are improving but still create uncertainty around normalized PAT/margins.